Clayton Partners LLC Invests $256,000 in Fennec Pharmaceuticals Inc (NASDAQ:FENC)

Clayton Partners LLC acquired a new position in Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 40,540 shares of the company's stock, valued at approximately $256,000. Clayton Partners LLC owned 0.15% of Fennec Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in FENC. Franklin Resources Inc. increased its stake in shares of Fennec Pharmaceuticals by 18.7% in the 3rd quarter. Franklin Resources Inc. now owns 14,799 shares of the company's stock worth $74,000 after acquiring an additional 2,330 shares in the last quarter. Pinnacle Wealth Planning Services Inc. bought a new position in shares of Fennec Pharmaceuticals during the fourth quarter valued at approximately $97,000. Barclays PLC lifted its holdings in shares of Fennec Pharmaceuticals by 274.3% during the third quarter. Barclays PLC now owns 31,319 shares of the company's stock valued at $157,000 after purchasing an additional 22,951 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Fennec Pharmaceuticals by 12.9% in the 4th quarter. Rhumbline Advisers now owns 34,299 shares of the company's stock worth $217,000 after purchasing an additional 3,911 shares in the last quarter. Finally, Advantage Alpha Capital Partners LP purchased a new stake in shares of Fennec Pharmaceuticals in the 3rd quarter worth approximately $264,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on FENC shares. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a report on Tuesday, March 11th. Wedbush reiterated an "outperform" rating and issued a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

Remove Ads

Insider Buying and Selling

In related news, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $6.66, for a total value of $66,600.00. Following the completion of the sale, the director now owns 76,294 shares of the company's stock, valued at $508,118.04. The trade was a 11.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 31,186 shares of company stock worth $203,389. 10.98% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Stock Down 0.7 %

Shares of Fennec Pharmaceuticals stock traded down $0.05 on Thursday, reaching $6.62. The company's stock had a trading volume of 97,534 shares, compared to its average volume of 111,605. Fennec Pharmaceuticals Inc has a 52 week low of $3.96 and a 52 week high of $11.49. The firm's fifty day simple moving average is $6.42 and its two-hundred day simple moving average is $5.65. The company has a market capitalization of $182.63 million, a price-to-earnings ratio of -66.19 and a beta of 0.36.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.